Table 3 Demographic characteristics of subjects with and without ESBL-producing E. coli acquisition during travel, number (%) of subjects (N = 58)
From: Antimicrobial resistance acquisition after international travel in U.S. travelers
|  | Non-ESBL E. coli (n = 53) | ESBL-producing E. coli (n = 5) |
|---|---|---|
Male gender | 23 (43) | 1 (20) |
Age, median (minimum-maximum) | 63 (15–82) | 67 (58–81) |
Regiona | ||
 Mexico, Caribbean, & Central America | 17 (32) | 1 (20) |
 Asia | 15 (28) | 2 (40) |
 Africa | 15 (28) | 1 (20) |
 Europe | 5 (9) | 0 |
 South America | 1 (2) | 1 (20) |
 North America | 2 (4) | 0 |
Purpose of travela | ||
 Vacation | 40 (76) | 3 (60) |
 Visiting friends and relatives | 10 (19) | 0 |
 Other (missionary/volunteer)* | 3 (6) | 2 (40) |
 Deployment and military duty | 4 (8) | 0 |
 School | 1 (2) | 0 |
Duration of travel, median (minimum-maximum) | 12 (6–105) | 11 (7–16) |
Living conditionsa | ||
 Hotel | 33 (62) | 3 (60) |
 Friends and relatives | 12 (23) | 1 (20) |
 Group livingb | 9 (17) | 1 (20) |
 Boat/cruise | 7 (13) | 0 |
Local water ingestion during travel | 26 (49) | 1 (20) |
Water exposures during travel | 19 (36) | 1 (20) |
Antibiotic exposure since enrollment | 20 (38) | 3 (60) |
 Malaria chemoprophylaxis | 19 (36) | 3 (60) |
  Atovaquone/Proguanil | 14 (26) | 3 (60) |
  Doxycycline | 3 (6) | 0 |
  Chloroquine | 2 (4) | 0 |
 Antibiotics for traveler’s diarrhea since enrollment | 2 (4) | 1 (20) |
  Ciprofloxacin | 1 (2) | 1 (20) |
  Erythromycin | 1 (2) | 0 |
 Systemic antibiotics for other indications since enrollment | 2 (4) | 1 (20) |
  Azithromycin | 1 (2) | 0 |
  Cephalexin | 1 (2) | 0 |
  Unknown antibiotic | 0 | 1 (20) |
Illness since enrollment | 11 (21) | 2 (40) |
Duration of illness, median (minimum-maximum) | 4 (1–27) | 5 (2–8) |